Announcements Trials
Browse Landscape

Phase

Phase 3 24Phase 2 12Phase 1 10Phase 4 4Phase NA 3Phase 1/2 3Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Conditions

Breast Neoplasms 264Carcinoma, Non-Small-Cell Lung 219Neoplasms 218Leukemia, Myeloid, Acute 193Multiple Myeloma 178Colorectal Neoplasms 175Melanoma 165Prostatic Neoplasms 163Lymphoma 145Leukemia 142Lymphoma, Non-Hodgkin 133Glioblastoma 131Pancreatic Neoplasms 127Neoplasm Metastasis 118Lung Neoplasms 118Leukemia, Lymphocytic, Chronic, B-Cell 118Ovarian Neoplasms 112Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Recurrence 97Myelodysplastic Syndromes 93Hodgkin Disease 92Lymphoma, Large B-Cell, Diffuse 89Lymphoma, Follicular 89Lymphoma, Mantle-Cell 83Head and Neck Neoplasms 79Carcinoma, Renal Cell 79Brain Neoplasms 77Sarcoma 73Carcinoma, Hepatocellular 73Squamous Cell Carcinoma of Head and Neck 71

Interventions

ranpirnase 1Human Papillomavirus Recombinant Vaccine nonavalent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × Condylomata Acuminata × Clear all
NCT05087849 2025-10-02

Intralesional HPV Vaccine for Condylomata

University of California, San Francisco

Phase 1/2 Completed
2 enrolled 7 charts

Condylomata Acuminata, Warts

NCT02535104 2018-06-06

Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)

Tamir Biotechnology, Inc.

Phase 1/2 Completed
70 enrolled

Condylomata Acuminata, Sexually Transmitted Diseases, Papillomavirus Infections

NCT01532102 2018-05-30

Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts

Vaxart

Phase 1/2 Completed
24 enrolled

Condylomata Acuminata, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡